NEW YORK (GenomeWeb News) – Agilent Technologies today said it will collaborate with Cell Line Genetics to develop high-throughput, genomic characterization workflows for confirming and monitoring the integrity of cell lines for translational and regenerative medicine research.

The workflows will be based on Agilent's CGH+SNP microarrays and SureFISH technologies. The arrays will be used to detect amplifications, deletions, and cell line clonality, while the FISH assays will be used to confirm aberrations "identified down to the single-cell level," said Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.